Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631757 | 1.00 | TSHR (0.33) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL14418876 | 0.85 | — | — | |
| SCHEMBL15653580 | 0.83 | TSHR (0.34) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL12638742 | 0.82 | GAA (0.38) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL14667853 | 0.82 | GAA (0.38) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL9622013 | 0.82 | — | — | |
| SCHEMBL6496531 | 0.81 | ALDH1A1 (0.39) | — | |
| SCHEMBL4180699 | 0.81 | PGD (0.33) | — | |
| SCHEMBL4180706 | 0.81 | PGD (0.33) | — | |
| SCHEMBL6484089 | 0.81 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103475-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250270209-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4522615-A1 | LRRK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4522616-A1 | LRRK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250066356-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-12202844-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| EP-3634430-B1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| EP-4370523-A1 | HETEROCYCLIC COMPOUNDS AS MAP4K1 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20140329771-A1 | STRUCTURAL VARIANTS OF MYCOLACTONES FOR USE IN MODULATING INFLAMMATION, IMMUNITY AND PAIN | INSTITUT PASTEUR (FR) | 2014-11-06 | — | — | US | disclosed |
| US-8471048-B2 | Ruthenium carbonyl complex having tridentate ligand, its production method and use | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-06-25 | — | — | US | disclosed |
| US-8471048-B2 | Ruthenium carbonyl complex having tridentate ligand, its production method and use | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-06-25 | — | — | US | disclosed |
| WO-2013072896-A1 | STRUCTURAL VARIANTS OF MYCOLACTONES FOR USE IN MODULATING INFLAMMATION, IMMUNITY AND PAIN | INSTITUT PASTEUR (FR) | 2013-05-23 | — | — | WO | disclosed |
| EP-2594561-A1 | Structural variants of mycolactones for use in modulating inflammation, immunity and pain | INSTITUT PASTEUR (FR) | 2013-05-22 | — | — | EP | disclosed |
| US-20120310000-A1 | ROSUVASTATIN CALCIUM INTERMEDIATE AND METHOD FOR PREPARING THE SAME | PORTON FINE CHEMICALS LTD. (CN) | 2012-12-06 | — | — | US | disclosed |
| US-20110237814-A1 | NOVEL RUTHENIUM CARBONYL COMPLEX HAVING TRIDENTATE LIGAND, ITS PRODUCTION METHOD AND USE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237814-A1 | NOVEL RUTHENIUM CARBONYL COMPLEX HAVING TRIDENTATE LIGAND, ITS PRODUCTION METHOD AND USE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-0269236-B1 | PROCESS FOR SYNTHESIS OF A CHIRAL AZETIDINONE | MERCK & CO. INC. (US) | 1991-04-03 | — | — | EP | disclosed |
| EP-0269236-A1 | Process for synthesis of a chiral azetidinone | MERCK & CO. INC. (US) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329771-A1 | STRUCTURAL VARIANTS OF MYCOLACTONES FOR USE IN MODULATING INFLAMMATION, IMMUNITY AND PAIN | IL1B, MYC, IL1A | TSHR 4844/4885HSD17B10 1059/4885MGAM 727/4885 |
| US-12202844-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | TSHR 4610/4885HSD17B10 2621/4885MGAM 3472/4885 |
| US-20250066356-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | TSHR 4664/4885HSD17B10 3433/4885MGAM 3200/4885 |
| US-20260103475-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K4 | TSHR 3148/4885HSD17B10 3016/4885MGAM 4659/4885 |
| US-20120310000-A1 | ROSUVASTATIN CALCIUM INTERMEDIATE AND METHOD FOR PREPARING THE SAME | ROS1, KCNN2, KCNN4 | TSHR 3934/4885HSD17B10 724/4885MGAM 1217/4885 |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VNN1, VKORC1, PANK3 | TSHR 3245/4885HSD17B10 596/4885MGAM 1946/4885 |
| US-20250270209-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | TSHR 4664/4885HSD17B10 3433/4885MGAM 3200/4885 |
| US-20110237814-A1 | NOVEL RUTHENIUM CARBONYL COMPLEX HAVING TRIDENTATE LIGAND, ITS PRODUCTION METHOD AND USE | ADH1C, ADH1A, ADH5 | TSHR 1289/4885HSD17B10 354/4885MGAM 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.